MoonLake Immunotherapeutics (MLTX) Financials

MLTX Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 400.4 million 146.4 million
Dec. 31, 2025 424.4 million 120.0 million
Sept. 30, 2025 414.3 million 123.1 million
June 30, 2025 460.1 million 102.2 million

MLTX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -66.3 million 13.4 million
Dec. 31, 2025 -58.8 million 3.6 million
Sept. 30, 2025 -44.5 million 3.7 million
June 30, 2025 -54.5 million 3.3 million

MLTX Net Income

No data available :(

MLTX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 357.9 million 99.9 million -
Dec. 31, 2025 394.0 million 74.5 million 374000
Sept. 30, 2025 380.5 million 73.7 million 486000
June 30, 2025 425.1 million 73.4 million 2.4 million

MLTX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 71.3 million
Dec. 31, 2025 64.5 million
Sept. 30, 2025 63.4 million
June 30, 2025 63.3 million

MLTX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 53.7 million 15.5 million -
Dec. 31, 2025 - 57.5 million 9.2 million -
Sept. 30, 2025 - 60.6 million 10.8 million -
June 30, 2025 - 49.0 million 10.9 million -

MLTX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 845000
Dec. 31, 2025 - 751000
Sept. 30, 2025 - 745000
June 30, 2025 - 742000

MLTX Revenue by Segment

Graph available only for paid members. Upgrade to see it.

MLTX

Price: $19.19

52 week price:
5.95
62.75

Earnings Per Share: -3.88 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 1.4 billion

Links: